Clinical Trials - News

Urologic Consultants participates in clinical trial for new ED drug

New Image

Avanafil (Stendra) was approved in April as the first new drug in nearly 10 years for the treatment of erectile dysfunction (ED). Urologic Consultants participated in the study of avanafil for the treatment of ED in men with diabetes.

Avanafi is a phosphodiesterase type 5 inhibitor (PDE5). It differs from other ED drugs in that it is fast-acting (as fast as 15 minutes) with possibly fewer side effects than ED drugs like Viagra. Reported mild side effects of Avanafil included headache, stuffy nose and cold-like symptoms, flushing and back pain.

Diagnosed and undiagnosed diabetes is estimated to affect approximately 13 million men in the United States. Complications of diabetes include heart disease, stoke, high blood pressure, neuropathy and ED. The prevalence of ED in men with diabetes may be as high as 71 percent.
Urologic Consults is currently participating in another Avanafil study. The objective of this study is to examine the therapeutic effects of two doses of Avanafil (100 mg and 200 mg) approximately 15 minutes after dosing in men with mild to severe ED.

For more information call the Urologic Consultants' Research line at (610) 667-0458.